Recent American news events range from horrifying to dystopian, but reading the applications of our fast.ai I was blown away by how many bright, creative, resourceful folks from all over the world are applying deep learning to tackle a variety of meaningful and interesting problems. Their passions range from ending illegal logging, diagnosing malaria in rural Uganda, translating Japanese manga, reducing farmer suicides in India via better loans, making Nigerian fashion recommendations, monitoring patients with Parkinson's disease, and more. Our mission at fast.ai is to make deep learning accessible to people from varied backgrounds outside of elite institutions, who are tackling problems in meaningful but low-resource areas, far from mainstream deep learning research. Our group of selected fellows for Deep Learning Part 2 includes people from Nigeria, Ivory Coast, South Africa, Pakistan, Bangladesh, India, Singapore, Israel, Canada, Spain, Germany, France, Poland, Russia, and Turkey.
An artist's impression of the European Space Agency's Rosetta probe, which aims to be the first to land on a comet. Several research groups, including a team led by geneticist Erika Sasaki and stem-cell biologist Hideyuki Okano at Keio University in Tokyo, hope to create transgenic primates with immune-system deficiencies or brain disorders. This could raise ethical concerns, but might bring us closer to therapies that are relevant to humans (mice can be poor models for such disorders). The work will probably make use of a gene-editing method called CRISPR, which saw rapid take-up last year. The European Space Agency's Rosetta spacecraft could become the first mission to land a probe on a comet.
As the smartphone falls in price while its capabilities improve, it is becoming a valuable tool in the diagnosis of a growing number of diseases and ailments around the world. When Yonatan Adiri's mother fell down a bank and briefly lost consciousness when travelling in China, an initial diagnosis suggested she had a few broken ribs, but nothing more serious. Doctors were keen to fly her to Hong Kong for treatment. But Yonatan's father was worried and took photos of the CT [computerised tomography] scans of the injuries, emailing them to his son. Yonatan showed the images to a trauma doctor, who instantly diagnosed a punctured lung.
IMAGE: InSilico study reveals how E64 approaches, binds to, and inhibits falcipain-2 of Plasmodium falciparum that causes malaria in humans. Monday, November 12, 2018, Taipei, Taiwan, Republic of China - Insilico Taiwan, a Taipei-based subsidiary of Insilico Medicine, developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, announces the publication of a new research paper titled "In Silico Study Reveals How E64 Approaches, Binds to, and Inhibits Falcipain-2 of Plasmodium falciparum that Causes Malaria in Humans" in Scientific Reports - a scientific journal published by the Nature Publishing Group. Malaria is one of the world's oldest infectious diseases that still causes a lot of health problems in many tropical countries. Plasmodium falciparum, the most dangerous human malaria parasite, is believed to cause hundreds of millions of illnesses and about half a million deaths a year. Inhibitors of FP2 block haemoglobin destruction and parasite development, suggesting that FP2 inhibition is a promising target for antimalarial therapy.
A cafe will open in Tokyo's Akasaka district in November featuring robot waiters remotely controlled from home by people with severe physical disabilities. The cafe, which will be open on weekdays between Nov. 26 to Dec. 7, will deploy OriHime-D robots controlled by disabled people with conditions such as amyotrophic lateral sclerosis, a form of motor neuron disease. The robot waiters, 1.2 meters tall and weighing 20 kg., will transmit video footage and audio via the internet, allowing their controllers to direct them from home via tablets or computers. At an event marking the OriHime-D's debut in August, a robot controlled by Nozomi Murata, who suffers from auto-phagic vacuolar myopathy that causes muscle weakness, asked a family if they would like some chocolate. "I want to create a world in which people who can't move their bodies can work too," said Kentaro Yoshifuji, chief executive officer of Ory Lab. Inc., the developer of the robots.